# Who does Thermo Fisher Scientific pay? Who are its key suppliers?
Canonical: https://valuechain.wiki/thermo-fisher-scientific · Facet: suppliers · Updated: 2026-09-12T00:51:23.908516+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Thermo Fisher Scientific discloses no named confirmed suppliers/cost counterparties; 2 relationships are tracked as undisclosed/aggregate. Per the valuechain.wiki graph: 2 cost edges, backed by 1 dated sources, 1 of them primary filings (as of 2026-09-12).

### Solventum 정제·여과 사업 (2025 인수 ~$40억) (high)  → /solventum.md
- note: A ~$4.0B acquisition completed in September 2025 that absorbed Solventum's bioprocessing filtration and membranes business — a bolt-on that extends Thermo Fisher's bioproduction consumables into purification/filtration and grows spend per CDMO/bioproduction customer (~$750M revenue). The latest execution of the 'scale is the moat' roll-up.
- [mentions] U.S. Securities and Exchange Commission (EN, filing, published 2026-02-26) https://www.sec.gov/Archives/edgar/data/97745/000009774526000018/tmo-20251231.htm: "FY2025 10-K: continues expansion M&A including the Purification & Filtration acquisition."
- [confirms] Business Wire (EN, news, published 2025-09-02) https://www.businesswire.com/news/home/20250902757637/en/Thermo-Fisher-Scientific-Completes-Acquisition-of-Solventums-Purification-and-Filtration-Business: "Thermo Fisher completed the acquisition of Solventum's Purification & Filtration business (Sep 2, 2025, ~$4.0B, water excluded), covering bioprocessing filtration, healthcare/industrial filtration and membranes."

### Olink (프로테오믹스, 2024 인수 ~$31억) (high)
- note: Acquired Sweden-based next-gen proteomics firm Olink for ~$3.1B in July 2024, folding it into the Life Sciences Solutions segment — a growth M&A that adds protein analysis to genomics, completing an 'all-omics' tools portfolio. Not a graph node (no cpid).
- [confirms] Thermo Fisher Scientific (EN, news, published 2024-07-10) https://ir.thermofisher.com/investors/news-events/news/news-details/2024/Thermo-Fisher-Scientific-Completes-Acquisition-of-Olink-Announces-Commencement-of-Subsequent-Offering-Period/default.aspx: "Thermo Fisher completed the Olink acquisition (July 2024, ~$3.1B); Olink joined the Life Sciences Solutions segment."

### 연구개발(R&D) (high)
- note: ~$1.4B annual R&D defends performance leadership in tools/reagents — sustaining new-product turnover atop scale to protect premium pricing.
- [confirms] U.S. Securities and Exchange Commission (EN, filing, published 2026-02-26) https://www.sec.gov/Archives/edgar/data/97745/000009774526000018/tmo-20251231.htm: "Research and development expenses were $1,397M in FY2025 ($1,390M in FY2024)."

### 원재료·부품 공급사 (high)
- note: Sources raw materials and components for in-house products — some regulated/design-specific items depend on single or few suppliers, so supply concentration is a latent cost/delivery bottleneck.
- [confirms] U.S. Securities and Exchange Commission (EN, filing, published 2026-02-26) https://www.sec.gov/Archives/edgar/data/97745/000009774526000018/tmo-20251231.htm: "We have a readily available supply of raw materials for all of our significant products from various sources. No single supplier is material, although for reasons of quality assurance, regulatory requirements, cost effectiveness, availability or uniqueness of design, certain materials or components may be sourced from a single supplier or a limited number of suppliers."

Reverse side: https://valuechain.wiki/thermo-fisher-scientific/customers.md · Ripple: https://valuechain.wiki/thermo-fisher-scientific/ripple.md

---
Full node: https://valuechain.wiki/thermo-fisher-scientific.md · JSON: https://valuechain.wiki/thermo-fisher-scientific.json